Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 27 of 41 · 1927 articles
If approved, a vedolizumab biosimilar could increase treatment options and competitive pricing for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The company already markets a natalizumab...
Researchers tested a ginger-derived glucan that reduced inflammation and reshaped the gut microbiota in a mouse colitis model — a potential prebiotic approach that could inform future IBD therapies or dietary strategies.
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
This study reports a new colon-targeted delivery system for unconjugated bilirubin that reduced inflammation and improved mucosal healing in a mouse model of ulcerative colitis; it could inform future drug-development...
This study expands knowledge of UC genetics in an understudied Indian population and points to genes and pathways that could help explain disease mechanisms different from those identified in Western cohorts. That could...
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
Diet can change gut microbes and their metabolites; this trial tests whether a high-protein, high-fiber diet can lower a microbe-derived compound (H2S) thought to be relevant in UC. If effective, diet-based approaches...
Surgical approach to creating an IPAA (j-pouch) affects timing and number of operations and recovery; trends toward more staged procedures may reflect increasing disease severity and preoperative treatment patterns that...
IBD is linked with mood and cognitive symptoms via systemic and gut‑brain inflammation, so preclinical findings that a cashew kernel extract reduced inflammation and behavioral changes could point to new research...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Depression is common in people with ulcerative colitis and affects quality of life and disease outcomes. Knowing research trends helps patients and clinicians see where evidence and care approaches are focused,...
Finding shared genes (CLDN8, ABCA12) suggests common inflammatory mechanisms between ulcerative colitis and psoriasis, which could inform future biomarkers or therapies relevant to patients with either or both...
The study shows a probiotic strain reduced inflammation and improved gut barrier and microbiome/metabolite profiles in a mouse colitis model, indicating a possible new avenue for UC therapies worth further research.
This study identifies a plant-derived compound that reduced inflammation and promoted intestinal healing in mouse models by modulating the Wnt/β-catenin pathway and ILC3-driven IL-22 production—pathways relevant to...
The study links patient-specific non-coding genetic variation to epithelial regulatory networks and to differences in disease severity and response in a large UC trial, suggesting genetics could help explain why some...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
People with Crohn’s or ulcerative colitis can rarely develop lung problems related to their disease or its treatments, and this review collates what is known about clinical features and therapies.
Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...
Based on the title and source metadata, this appears to be a case report related to Ulcerative colitis and Complications. The original article is from Cureus.
UGI involvement in children with IBD was common and linked to a more severe disease course — lower remission rates and more frequent need for biologic therapy — which could affect monitoring and treatment planning.
Dietary patterns are being studied as therapies for pediatric IBD because they may help induce remission or improve disease control without drugs.
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemistry and Biophysics Reports.
This trial tests a new oral drug (Alpha-0261) for moderate-to-severe ulcerative colitis and could matter to people who haven’t responded to standard medicines. Early-phase studies mainly assess safety but also collect...
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
FAP appears linked to both inflammation and fibrosis in IBD; distinguishing cellular versus extracellular FAP might help develop or validate fibrosis biomarkers that detect fibrostenotic disease.
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.
The appendix in conventional UC appears to be inflamed early and then remodels to fibrous obliteration over decades, which could influence thinking about timing or rationale for appendectomy-based interventions.
Older adults with UC face different risks and treatment trade-offs than younger patients — higher infection and cancer risks, medication toxicities, and challenges with diagnosis and colonoscopy. Understanding these...
MSCs are an active research area for IBD because they may reduce harmful immune activity and help heal intestinal tissue. Patients following emerging biologic and cell therapies may want to know how MSCs could fit into...
Surgery for IBD has become less common since modern biologic therapies, but a noticeable number of patients—especially with Crohn’s disease and poor nutrition—still progress to operations. Understanding who remains at...
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
The study explores a multi-herb formula that the authors report reduces inflammation and alters gut microbiota in a mouse model of ulcerative colitis, suggesting possible biological mechanisms worth further study.
The study identifies macrophage-derived microvesicles as modulators of intestinal barrier function and ER stress in ulcerative colitis models, suggesting a new mechanism that could be relevant to mucosal healing...
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.
This study could validate a noninvasive stool-test strategy (FIT + fecal calprotectin) to triage which long-standing UC patients need colonoscopy, potentially improving surveillance efficiency and adherence.
People with IBD may have a higher-than-expected rate of biopsy-confirmed celiac disease in this Northern Indian cohort, and standard anti-tTG blood tests can be falsely positive in IBD. Confirmatory duodenal biopsy is...
This study suggests plant-derived exosome-like nanoparticles from a traditional herbal decoction may reduce inflammation, oxidative stress, and alter gut microbiota in a mouse model of colitis — an early preclinical step...
